Clinical Trial Update: Phase 2, Observer-Blind, Placebo-Controlled, Randomized, Multi-Center Extension Study to Evaluate the Safety and Immunogenicity of a Booster Dose of a MenABCWY Vaccine Administered 24 Months Following the Primary Series to Adolescents and Young Adults Who Participated in V102_03 (NCT01272180) [Phase 2]

View source ↗

Summary

This Phase 2 extension study evaluated the safety and immunogenicity of a booster dose of the MenABCWY meningococcal vaccine given 24 months after the primary s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Disease

Drugs mentioned

• MenABCWY vaccine

Snippet

Sponsor: Novartis Vaccines | Conditions: Meningococcal Disease | Phase 2 | Status: COMPLETED | Results posted: 2016-10-25